RESUMO

PURPOSE: NAFLD is a hepatic component of type 2 diabetes mellitus (T2D), in which impaired hepatic glucose production plays an important role. Inhibitors of sodium glucose transporter 2 (SGLT2) reduce glycemia and exert beneficial effects on diabetic complications. Recently, dual SGLT1/2 inhibition has been proposed to be more effective in reducing glycemia. We hypothesized that improving hepatic glucose metabolism induced by SGLT1/2 inhibition could be accompanied by beneficial effects on NAFLD progression. METHODS: Glycemic homeostasis, hepatic glucose production and NAFLD features were investigated in obese T2D mice, treated with SGLT1/2 inhibitor phlorizin for 1 week. RESULTS: T2D increased glycemia; insulinemia; hepatic expression of phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase) and glucose transporter 2 (Slc2a2 gene); hepatocyte nuclear factors 1A/4A/3B-binding activity in Slc2a2; endogenous glucose production; liver weight, plasma transaminase concentration as well as hepatic inflammation markers, and induced histological signals of non-alcoholic steatohepatitis (NASH, according to NASH-CRN Pathology Committee System). Phlorizin treatment restored all these parameters (mean NASH score reduced from 5.25 to 2.75 P<0.001); however, plasma transaminase concentration was partially reverted and some hepatic inflammation markers remained unaltered. CONCLUSION: NAFLD accompanies altered hepatic glucose metabolism in T2D mice and that greatly ameliorated through short-term treatment with the dual SGLT1/2 inhibitor. This suggests that altered hepatic glucose metabolism participates in T2D-related NAFLD and highlights the pharmacological inhibition of SGLTs as a useful approach not only for controlling glycemia but also for mitigating development and/or progression of NAFLD.

RESUMO

Our data proposes that glucose is transferred directly to the cerebrospinal fluid (CSF) of the hypothalamic ventricular cavity through a rapid "fast-track-type mechanism" that would efficiently stimulate the glucosensing areas. This mechanism would occur at the level of the median eminence (ME), a periventricular hypothalamic zone with no blood-brain barrier. This "fast-track" mechanism would involve specific glial cells of the ME known as ß2 tanycytes that could function as "inverted enterocytes," expressing low-affinity glucose transporters GLUT2 and GLUT6 in order to rapidly transfer glucose to the CSF. Due to the large size of tanycytes, the presence of a high concentration of mitochondria and the expression of low-affinity glucose transporters, it would be expected that these cells accumulate glucose in the endoplasmic reticulum (ER) by sequestering glucose-6-phosphate (G-6-P), in a similar way to that recently demonstrated in astrocytes. Glucose could diffuse through the cells by micrometric distances to be released in the apical region of ß2 tanycytes, towards the CSF. Through this mechanism, levels of glucose would increase inside the hypothalamus, stimulating glucosensing mechanisms quickly and efficiently. KEY MESSAGES: • Glucose diffuses through the median eminence cells (ß2 tanycytes), towards the hypothalamic CSF. • Glucose is transferred through a rapid "fast-track-type mechanism" via GLUT2 and GLUT6. • Through this mechanism, hypothalamic glucose levels increase, stimulating glucosensing.

Assuntos

Barreira Hematoencefálica/metabolismo , Glucose/metabolismo , Hipotálamo/metabolismo , Mitocôndrias/metabolismo , Animais , Transporte Biológico Ativo/fisiologia , Regulação da Expressão Gênica/fisiologia , Masculino , Ratos , Ratos Sprague-Dawley

RESUMO

The intestinal physiology and mechanisms involved in nutrient transport are not well established in quails (Coturnix coturnix japonica). The present study assessed the growth performance, morphological development, duodenal density and the expression of Sglt1 and Glut2 of female Japanese quails from 1 to 49 days of age. The three small intestine segments were sampled weekly from 1 to 49 days of age to evaluate villus height, crypt depth and villus: crypt ratio, and goblet cell counts. Scanning electronic microscopy was used to determine duodenal villus density, and real-time polymerase chain reaction (qPCR) was used to study the sodium/glucose cotransporter-1 Sglt1 and glucose transporter Glut2 in the jejunum. Villus height and crypt depth in the duodenum, jejunum and ileum increased with age until 42 and 49 days of age (P < 0.001), and regression analysis evidenced a quadratic effect (P < 0.0001), indicating increasing values to a maximum and then a decrease afterwards. Goblet cell counts increased (P < 0.001) in duodenum, jejunum and ileum from 1 to 42 days, decreasing at 49 days, which was also corroborated by the regression analysis. Villus density in the duodenum was greater in the first week, decreased with age and increased again at 42 days, probably due to the proximity with egg production onset. The expression of Sglt1 and Glut2 mRNA in the jejunum varied with age. In conclusion, the intestinal mucosa of female Japanese quail developed morphologically until 42days and functionally until earlier ages, indicating an adaptation to the exogenous diet during the first weeks of life.

Assuntos

Proteínas Aviárias/genética , Coturnix , Transportador de Glucose Tipo 2/genética , Mucosa Intestinal/metabolismo , Transportador 1 de Glucose-Sódio/genética , Animais , Coturnix/anatomia & histologia , Coturnix/genética , Coturnix/crescimento & desenvolvimento , Coturnix/metabolismo , Feminino , Mucosa Intestinal/ultraestrutura , Microscopia Eletrônica de Varredura , RNA Mensageiro/metabolismo

RESUMO

ABSTRACT Recently, lupin seed (Lupinus albus L., Fabaceae) products have emerged as a functional food due to their nutritional and health benefits. Numerous reports have demonstrated the hypoglycemic effects of lupin's gamma conglutin protein; nonetheless, its mechanism of action remains elusive. To understand the role of this protein on glucose metabolism, we evaluated the effect of administering L. albus' gamma conglutin on Slc2a2, Gck, and Pdx-1 gene expression as well as GLUT2 protein tissue levels in streptozotocin-induced diabetic rats. While consuming their regular diet, animals received a daily gamma conglutin dose (120 mg/kg per body weight) for seven consecutive days. Serum glucose levels were measured at the beginning and at the end of the experimental period. At the end of the trial, we quantified gene expression in pancreatic and hepatic tissues as well as GLUT2 immunopositivity in Langerhans islets. Gamma conglutin administration lowered serum glucose concentration by 17.7%, slightly increased Slc2a2 and Pdx-1 mRNA levels in pancreas, up-regulated Slc2a2 expression in the liver, but it had no effect on hepatic Gck expression. After gamma conglutin administration, GLUT2 immunopositivity in Langerhans islets of diabetic animals resembled that of healthy rats. In conclusion, our results indicate that gamma conglutin up-regulates Slc2a2 gene expression in liver and normalizes GLUT2 protein content in pancreas of streptozotocin-induced rats.

RESUMO

Glucose is a key modulator of feeding behavior. By acting in peripheral tissues and in the central nervous system, it directly controls the secretion of hormones and neuropeptides and modulates the activity of the autonomic nervous system. GLUT2 is required for several glucoregulatory responses in the brain, including feeding behavior, and is localized in the hypothalamus and brainstem, which are the main centers that control this behavior. In the hypothalamus, GLUT2 has been detected in glial cells, known as tanycytes, which line the basal walls of the third ventricle (3V). This study aimed to clarify the role of GLUT2 expression in tanycytes in feeding behavior using 3V injections of an adenovirus encoding a shRNA against GLUT2 and the reporter EGFP (Ad-shGLUT2). Efficient in vivo GLUT2 knockdown in rat hypothalamic tissue was demonstrated by qPCR and Western blot analyses. Specificity of cell transduction in the hypothalamus and brainstem was evaluated by EGFP-fluorescence and immunohistochemistry, which showed EGFP expression specifically in ependymal cells, including tanycytes. The altered mRNA levels of both orexigenic and anorexigenic neuropeptides suggested a loss of response to increased glucose in the 3V. Feeding behavior analysis in the fasting-feeding transition revealed that GLUT2-knockdown rats had increased food intake and body weight, suggesting an inhibitory effect on satiety. Taken together, suppression of GLUT2 expression in tanycytes disrupted the hypothalamic glucosensing mechanism, which altered the feeding behavior.

Assuntos

Comportamento Alimentar/fisiologia , Transportador de Glucose Tipo 2/metabolismo , Hipotálamo/metabolismo , Neuroglia/metabolismo , Saciação/fisiologia , Animais , Peso Corporal , Tronco Encefálico/citologia , Tronco Encefálico/metabolismo , Células Cultivadas , Jejum/metabolismo , Técnicas de Silenciamento de Genes , Transportador de Glucose Tipo 2/genética , Hipotálamo/citologia , Masculino , Neuroglia/citologia , Neuropeptídeos/metabolismo , RNA Mensageiro/metabolismo , Ratos Sprague-Dawley

RESUMO

Liver X receptors (LXR) are important transcription factors involved in the regulation of carbohydrate and lipid metabolism. Recently, we described LXR receptors expression in the hypothalamus but their function in this brain area remains unknown. Here, we evaluated the function of LXR on the expression of factors produced in the hypothalamus in vitro and in vivo by Western blotting and immunocytochemistry. More precisely we studied the expression of GnRH and GHRH, αMSH and NPY in male Sprague-Dawley rats. The effects of two synthetic LXR agonists, T0901317 and GW3965, were first tested in vitro. Hypothalamic explants were treated with either T0901317 or GW3965 (10µM) for 2, 4, 6 and 8h. As a positive control the cholesterol ABCA1 and glucose GLUT2 transporters were used. No changes were observed in the expression of the factors evaluated in vitro. The effects of the LXR agonists were then tested in vivo. Rats were injected ICV into the third ventricle with either T0901317 or GW3965 (2.5µg/5µL ICV) and after 3.5h or 24h the hypothalami were dissected out and rapidly frozen for analysis. αMSH and GnRH expression was significantly increased after 3.5h of T0901317 treatment. Anterior/posterior hypothalamic ratio increases for αMSH expression and decreases for GnRH expression after 24h of LXR activation. Altogether these results show that LXR activation affects the expression of GnRH and αMSH, suggesting that LXR in the hypothalamus is capable of modulating hypothalamic responses related to appetite, sexual behavior and reproductive functions.

Assuntos

Hormônio Liberador de Gonadotropina/biossíntese , Hipotálamo/metabolismo , Receptores X do Fígado/metabolismo , alfa-MSH/biossíntese , Animais , Expressão Gênica , Hormônio Liberador de Gonadotropina/genética , Hidrocarbonetos Fluorados/farmacologia , Hipotálamo/efeitos dos fármacos , Receptores X do Fígado/agonistas , Masculino , Ratos , Ratos Sprague-Dawley , Sulfonamidas/farmacologia , alfa-MSH/genética

RESUMO

Insulin resistance participates in the glycaemic control disruption in type 2 diabetes mellitus (T2DM), by reducing muscle glucose influx and increasing liver glucose efflux. GLUT4 (Slc2a4 gene) and GLUT2 (Slc2a2 gene) proteins play a fundamental role in the muscle and liver glucose fluxes, respectively. Resveratrol is a polyphenol suggested to have an insulin sensitizer effect; however, this effect, and related mechanisms, have not been clearly demonstrated in T2DM. We hypothesized that resveratrol can improve glycaemic control by restoring GLUT4 and GLUT2 expression in muscle and liver. Mice were rendered obese T2DM in adult life by neonatal injection of monosodium glutamate. Then, T2DM mice were treated with resveratrol for 60 days or not. Glycaemic homeostasis, GLUT4, GLUT2, and SIRT1 (sirtuin 1) proteins (Western blotting); Slc2a4, Slc2a2, and Pck1 (key gluconeogenic enzyme codifier) mRNAs (RT-qPCR); and hepatic glucose efflux were analysed. T2DM mice revealed: high plasma concentration of glucose, fructosamine, and insulin; insulin resistance (insulin tolerance test); decreased Slc2a4/GLUT4 content in gastrocnemius and increased Slc2a2/GLUT2 content in liver; and increased Pck1 mRNA and gluconeogenic activity (pyruvate tolerance test) in liver. All alterations were restored by resveratrol treatment. Additionally, in both muscle and liver, resveratrol increased SIRT1 nuclear content, which must participate in gene expression regulations. In sum, the results indisputably reveals that resveratrol improves glycaemic control in T2DM, and that involves an increase in muscle Slc2a4/GLUT4 and a decrease in liver Slc2a2/GLUT2 expression. This study contributes to our understanding how resveratrol might be prescribed for T2DM according to the principles of evidence-based medicine.

Assuntos

Glicemia/efeitos dos fármacos , Diabetes Mellitus Tipo 2/tratamento farmacológico , Regulação da Expressão Gênica/efeitos dos fármacos , Estilbenos/metabolismo , Estilbenos/farmacologia , Animais , Glucose/metabolismo , Transportador de Glucose Tipo 2/efeitos dos fármacos , Transportador de Glucose Tipo 2/genética , Transportador de Glucose Tipo 4/efeitos dos fármacos , Transportador de Glucose Tipo 4/genética , Humanos , Insulina/metabolismo , Resistência à Insulina , Fígado/metabolismo , Masculino , Camundongos , Camundongos Obesos , Músculo Esquelético/metabolismo , RNA Mensageiro/efeitos dos fármacos , Resveratrol , Sirtuína 1

RESUMO

Se reporta un caso de Síndrome de Fanconi- Bickel, un tipo raro de enfermedad del metabolismo de los carbohidratos. La presentación clínica se da en los primeros meses de vida con retardo del crecimiento, hepatomegalia, hipoglicemia en ayuno, raquitismo y disfunción tubular renal proximal. La orientación diagnóstica se establece sobre la base de manifestaciones clínicas, hallazgos radiológicos de raquitismo y a partir de resultados característicos de las investigaciones de laboratorio que muestran disfunción tubular proximal, caracterizada por glucosuria con hipoglicemia en ayunas, acidosis metabólica, hipofosfatemia, fosfaturia, aminoaciduria. Fue descrito en 1949 por Fanconi y Bickel y es ocasionado por mutaciones en el transportador facilitado de glucosa GLUT 2.

---

We present a case of Fanconi- Bickel Syndrome, a rare type of carbohydrate metabolism disorder. Clinical presentation begins during the first months of life with failure to thrive, hepatomegaly, fasting hypoglycemia, rickets and renal proximal tubular dysfunction. Diagnosis is established on the basis of clinical manifestations, radiological findings of rickets, and laboratory investigations showing proximal tubular dysfunction, characterized by glucosuria with fasting hypoglycemia, metabolic acidosis, hypophosphatemia, phosphaturia and aminoaciduria. It was described in 1949 by Fanconi and Bick.

RESUMO

Abstract Fanconi-Bickel syndrome (FBS), also known as glycogen storage disease type XI (GSD XI), is a rare autosomal recessive disorder of carbohydrate metabolism. It is caused by mutations in the gene SLC2A2, which encodes for the facilitative glucose transporter GLUT2. Diagnosis of FBS is often delayed since the clinical features and laboratory markers often overlap with other disorders whose characteristic features include short stature, fasting hypoglycemia, postprandial hyperglycemia, hepatomegaly, hypophosphatemic rickets, and proximal renal tubular dysfunction. In this article, we present a case of FBS and its management in an African American female who initially presented with persistent proximal tubulopathy, hypercalciuria, and metabolic acidosis. We also include a recent literature review on FBS and discuss other metabolic disorders that should be considered in the differential diagnosis.

RESUMO

AIMS: Solute carrier 2a2 (Slc2a2) gene codifies the glucose transporter GLUT2, a key protein for glucose flux in hepatocytes and renal epithelial cells of proximal tubule. In diabetes mellitus, hepatic and tubular glucose output has been related to Slc2a2/GLUT2 overexpression; and controlling the expression of this gene may be an important adjuvant way to improve glycemic homeostasis. Thus, the present study investigated transcriptional mechanisms involved in the diabetes-induced overexpression of the Slc2a2 gene. MAIN METHODS: Hepatocyte nuclear factors 1α and 4α (HNF-1α and HNF-4α), forkhead box A2 (FOXA2), sterol regulatory element binding protein-1c (SREBP-1c) and the CCAAT-enhancer-binding protein (C/EBPß) mRNA expression (RT-PCR) and binding activity into the Slc2a2 promoter (electrophoretic mobility assay) were analyzed in the liver and kidney of diabetic and 6-day insulin-treated diabetic rats. KEY FINDINGS: Slc2a2/GLUT2 expression increased by more than 50% (P<0.001) in the liver and kidney of diabetic rats, and 6-day insulin treatment restores these values to those observed in non-diabetic animals. Similarly, the mRNA expression and the binding activity of HNF-1α, HNF-4α and FOXA2 increased by 50 to 100% (P<0.05 to P<0.001), also returning to values of non-diabetic rats after insulin treatment. Neither the Srebf1 and Cebpb mRNA expression, nor the SREBP-1c and C/EBP-ß binding activity was altered in diabetic rats. SIGNIFICANCE: HNF-1α, HNF-4α and FOXA2 transcriptional factors are involved in diabetes-induced overexpression of Slc2a2 gene in the liver and kidney. These data point out that these transcriptional factors are important targets to control GLUT2 expression in these tissues, which can contribute to glycemic homeostasis in diabetes.

Assuntos

Diabetes Mellitus Experimental/genética , Transportador de Glucose Tipo 2/genética , Fator 1-alfa Nuclear de Hepatócito/genética , Fator 3-beta Nuclear de Hepatócito/genética , Fator 4 Nuclear de Hepatócito/genética , Rim/metabolismo , Fígado/metabolismo , Animais , Sítios de Ligação , Proteína beta Intensificadora de Ligação a CCAAT/genética , Diabetes Mellitus Experimental/tratamento farmacológico , Diabetes Mellitus Experimental/metabolismo , Regulação da Expressão Gênica/efeitos dos fármacos , Transportador de Glucose Tipo 2/metabolismo , Fator 1-alfa Nuclear de Hepatócito/metabolismo , Fator 3-beta Nuclear de Hepatócito/metabolismo , Fator 4 Nuclear de Hepatócito/metabolismo , Insulina/farmacologia , Rim/efeitos dos fármacos , Fígado/efeitos dos fármacos , Masculino , Regiões Promotoras Genéticas , Ratos , Ratos Wistar , Proteína de Ligação a Elemento Regulador de Esterol 1/genética

RESUMO

It has recently been proposed that hypothalamic glial cells sense glucose levels and release lactate as a signal to activate adjacent neurons. GK (glucokinase), the hexokinase involved in glucose sensing in pancreatic beta-cells, is also expressed in the hypothalamus. However, it has not been clearly determined if glial and/or neuronal cells express this protein. Interestingly, tanycytes, the glia that cover the ventricular walls of the hypothalamus, are in contact with CSF (cerebrospinal fluid), the capillaries of the arcuate nucleus and adjacent neurons; this would be expected for a system that can detect and communicate changes in glucose concentration. Here, we demonstrated by Western-blot analysis, QRT-PCR [quantitative RT-PCR (reverse transcription-PCR)] and in situ hybridization that GK is expressed in tanycytes. Confocal microscopy and immuno-ultrastructural analysis revealed that GK is localized in the nucleus and cytoplasm of beta1-tanycytes. Furthermore, GK expression increased in these cells during the second week of post-natal development. Based on this evidence, we propose that tanycytes mediate, at least in part, the mechanism by which the hypothalamus detects changes in glucose concentrations.

Assuntos

Regulação da Expressão Gênica no Desenvolvimento , Regulação Enzimológica da Expressão Gênica , Glucoquinase/biossíntese , Hipotálamo/enzimologia , Hipotálamo/crescimento & desenvolvimento , Neuroglia/enzimologia , Fatores Etários , Animais , Animais Recém-Nascidos , Diferenciação Celular/genética , Glucoquinase/genética , Hipotálamo/citologia , Neuroglia/citologia , Ratos , Ratos Sprague-Dawley

RESUMO

Many advances have been made in the understanding of intestinal electrolyte transport from the molecular to the whole-tissue level. This chapter discusses the molecular mechanisms of intestinal epithelial ion transport processes, as well as the intra- and extracellular factors involved in their regulation, as a framework for the understanding of virus-induced gastroenteritis. Based on the present knowledge of the effects of rotavirus (RV) infection on the physiology of the intestine at different levels of organization, a working model for the pathogenesis of RV diarrhea is presented in the chapter. The understanding of the pathogenic processes of viral diarrheas may serve as the basis for a rational approach in the design of novel therapeutic strategies and the search for new antiviral drugs.